{"entity":{"type":"insider","cik":"0001423786","url":"/insider/0001423786","json_url":"/insider/0001423786.json","name":"Sarena Francis Willard","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":12,"n_filings":5,"first":"2016-01-29","last":"2017-01-18","span_basis":"filed_date"},"name_variants":[{"name":"Sarena Francis Willard","source":"filing","n_filings":5,"first_seen":"2016-01-29","last_seen":"2017-01-18"}],"transactions":[{"id":5308374,"accession":"0001209191-17-004336","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-17-004336","line_url":"/filing/0001209191-17-004336#line-2","is_derivative":false,"issuer_cik":"0001175505","issuer_name":"FIVE PRIME THERAPEUTICS INC","issuer_ticker":"FPRX","issuer_name_source":null,"issuer_url":"/issuer/0001175505","owner_cik":"0001423786","owner_name":"Sarena Francis Willard","owner_url":"/insider/0001423786","role":"Officer (Chief Strategy Officer)","officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3636.0,"shares_display":"3,636","price_per_share":47.39,"price_display":"47.39","price_state":"stated","total_value":172310.04,"total_display":"172,310.04","shares_owned_after":78824.0,"shares_owned_after_display":"78,824","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-01-18","filed_date":"2017-01-18","scope":"insider"},{"id":2062019,"accession":"0001209191-16-152411","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-152411","line_url":"/filing/0001209191-16-152411#line-2","is_derivative":false,"issuer_cik":"0001175505","issuer_name":"FIVE PRIME THERAPEUTICS INC","issuer_ticker":"FPRX","issuer_name_source":null,"issuer_url":"/issuer/0001175505","owner_cik":"0001423786","owner_name":"Sarena Francis Willard","owner_url":"/insider/0001423786","role":"Officer (Chief Strategy Officer)","officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1710.0,"shares_display":"1,710","price_per_share":60.14,"price_display":"60.14","price_state":"stated","total_value":102839.4,"total_display":"102,839.40","shares_owned_after":81266.0,"shares_owned_after_display":"81,266","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-11-28","filed_date":"2016-11-30","scope":"insider"},{"id":2141520,"accession":"0001209191-16-152233","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-16-152233","line_url":"/filing/0001209191-16-152233#line-5","is_derivative":false,"issuer_cik":"0001175505","issuer_name":"FIVE PRIME THERAPEUTICS INC","issuer_ticker":"FPRX","issuer_name_source":null,"issuer_url":"/issuer/0001175505","owner_cik":"0001423786","owner_name":"Sarena Francis Willard","owner_url":"/insider/0001423786","role":"Officer (Chief Strategy Officer)","officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21189.0,"shares_display":"21,189","price_per_share":60.48,"price_display":"60.48","price_state":"stated","total_value":1281510.72,"total_display":"1,281,510.72","shares_owned_after":81266.0,"shares_owned_after_display":"81,266","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-11-25","filed_date":"2016-11-28","scope":"insider"},{"id":2141512,"accession":"0001209191-16-152233","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-152233","line_url":"/filing/0001209191-16-152233#line-2","is_derivative":false,"issuer_cik":"0001175505","issuer_name":"FIVE PRIME THERAPEUTICS INC","issuer_ticker":"FPRX","issuer_name_source":null,"issuer_url":"/issuer/0001175505","owner_cik":"0001423786","owner_name":"Sarena Francis Willard","owner_url":"/insider/0001423786","role":"Officer (Chief Strategy Officer)","officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13465.0,"shares_display":"13,465","price_per_share":60.23,"price_display":"60.23","price_state":"stated","total_value":810996.95,"total_display":"810,996.95","shares_owned_after":81266.0,"shares_owned_after_display":"81,266","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-11-23","filed_date":"2016-11-28","scope":"insider"},{"id":2316872,"accession":"0001209191-16-111281","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-16-111281","line_url":"/filing/0001209191-16-111281#line-4","is_derivative":false,"issuer_cik":"0001175505","issuer_name":"FIVE PRIME THERAPEUTICS INC","issuer_ticker":"FPRX","issuer_name_source":null,"issuer_url":"/issuer/0001175505","owner_cik":"0001423786","owner_name":"Sarena Francis Willard","owner_url":"/insider/0001423786","role":"Officer (EVP, Gen Counsel and Secretary)","officer_title":"EVP, Gen Counsel and Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5550.0,"shares_display":"5,550","price_per_share":40.01,"price_display":"40.01","price_state":"stated","total_value":222055.5,"total_display":"222,055.50","shares_owned_after":83834.0,"shares_owned_after_display":"83,834","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-03-30","filed_date":"2016-03-31","scope":"insider"},{"id":2316864,"accession":"0001209191-16-111281","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-111281","line_url":"/filing/0001209191-16-111281#line-2","is_derivative":false,"issuer_cik":"0001175505","issuer_name":"FIVE PRIME THERAPEUTICS INC","issuer_ticker":"FPRX","issuer_name_source":null,"issuer_url":"/issuer/0001175505","owner_cik":"0001423786","owner_name":"Sarena Francis Willard","owner_url":"/insider/0001423786","role":"Officer (EVP, Gen Counsel and Secretary)","officer_title":"EVP, Gen Counsel and Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4450.0,"shares_display":"4,450","price_per_share":40.0,"price_display":"40.00","price_state":"stated","total_value":178000.0,"total_display":"178,000.00","shares_owned_after":83834.0,"shares_owned_after_display":"83,834","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-03-29","filed_date":"2016-03-31","scope":"insider"},{"id":2426544,"accession":"0001123292-16-001659","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001123292-16-001659","line_url":"/filing/0001123292-16-001659#line-11","is_derivative":false,"issuer_cik":"0001175505","issuer_name":"FIVE PRIME THERAPEUTICS INC","issuer_ticker":"FPRX","issuer_name_source":null,"issuer_url":"/issuer/0001175505","owner_cik":"0001423786","owner_name":"Sarena Francis Willard","owner_url":"/insider/0001423786","role":"Officer (EVP, Gen Counsel & Secretary)","officer_title":"EVP, Gen Counsel & Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7768.0,"shares_display":"7,768","price_per_share":34.73,"price_display":"34.73","price_state":"stated","total_value":269782.64,"total_display":"269,782.64","shares_owned_after":83570.0,"shares_owned_after_display":"83,570","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-01-27","filed_date":"2016-01-29","scope":"insider"},{"id":2426542,"accession":"0001123292-16-001659","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001123292-16-001659","line_url":"/filing/0001123292-16-001659#line-10","is_derivative":false,"issuer_cik":"0001175505","issuer_name":"FIVE PRIME THERAPEUTICS INC","issuer_ticker":"FPRX","issuer_name_source":null,"issuer_url":"/issuer/0001175505","owner_cik":"0001423786","owner_name":"Sarena Francis Willard","owner_url":"/insider/0001423786","role":"Officer (EVP, Gen Counsel & Secretary)","officer_title":"EVP, Gen Counsel & Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7449.0,"shares_display":"7,449","price_per_share":35.11,"price_display":"35.11","price_state":"stated","total_value":261534.39,"total_display":"261,534.39","shares_owned_after":83570.0,"shares_owned_after_display":"83,570","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-01-27","filed_date":"2016-01-29","scope":"insider"},{"id":2426539,"accession":"0001123292-16-001659","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001123292-16-001659","line_url":"/filing/0001123292-16-001659#line-9","is_derivative":false,"issuer_cik":"0001175505","issuer_name":"FIVE PRIME THERAPEUTICS INC","issuer_ticker":"FPRX","issuer_name_source":null,"issuer_url":"/issuer/0001175505","owner_cik":"0001423786","owner_name":"Sarena Francis Willard","owner_url":"/insider/0001423786","role":"Officer (EVP, Gen Counsel & Secretary)","officer_title":"EVP, Gen Counsel & Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6895.0,"shares_display":"6,895","price_per_share":35.55,"price_display":"35.55","price_state":"stated","total_value":245117.25,"total_display":"245,117.25","shares_owned_after":86154.0,"shares_owned_after_display":"86,154","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-01-27","filed_date":"2016-01-29","scope":"insider"},{"id":2426535,"accession":"0001123292-16-001659","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001123292-16-001659","line_url":"/filing/0001123292-16-001659#line-8","is_derivative":false,"issuer_cik":"0001175505","issuer_name":"FIVE PRIME THERAPEUTICS INC","issuer_ticker":"FPRX","issuer_name_source":null,"issuer_url":"/issuer/0001175505","owner_cik":"0001423786","owner_name":"Sarena Francis Willard","owner_url":"/insider/0001423786","role":"Officer (EVP, Gen Counsel & Secretary)","officer_title":"EVP, Gen Counsel & Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3791.0,"shares_display":"3,791","price_per_share":35.31,"price_display":"35.31","price_state":"stated","total_value":133860.21,"total_display":"133,860.21","shares_owned_after":83570.0,"shares_owned_after_display":"83,570","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-01-27","filed_date":"2016-01-29","scope":"insider"},{"id":2426532,"accession":"0001123292-16-001659","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001123292-16-001659","line_url":"/filing/0001123292-16-001659#line-7","is_derivative":false,"issuer_cik":"0001175505","issuer_name":"FIVE PRIME THERAPEUTICS INC","issuer_ticker":"FPRX","issuer_name_source":null,"issuer_url":"/issuer/0001175505","owner_cik":"0001423786","owner_name":"Sarena Francis Willard","owner_url":"/insider/0001423786","role":"Officer (EVP, Gen Counsel & Secretary)","officer_title":"EVP, Gen Counsel & Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2584.0,"shares_display":"2,584","price_per_share":36.13,"price_display":"36.13","price_state":"stated","total_value":93359.92,"total_display":"93,359.92","shares_owned_after":83570.0,"shares_owned_after_display":"83,570","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-01-27","filed_date":"2016-01-29","scope":"insider"},{"id":2426528,"accession":"0001123292-16-001659","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001123292-16-001659","line_url":"/filing/0001123292-16-001659#line-6","is_derivative":false,"issuer_cik":"0001175505","issuer_name":"FIVE PRIME THERAPEUTICS INC","issuer_ticker":"FPRX","issuer_name_source":null,"issuer_url":"/issuer/0001175505","owner_cik":"0001423786","owner_name":"Sarena Francis Willard","owner_url":"/insider/0001423786","role":"Officer (EVP, Gen Counsel & Secretary)","officer_title":"EVP, Gen Counsel & Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1513.0,"shares_display":"1,513","price_per_share":35.0,"price_display":"35.00","price_state":"stated","total_value":52955.0,"total_display":"52,955.00","shares_owned_after":83570.0,"shares_owned_after_display":"83,570","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-01-27","filed_date":"2016-01-29","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":12,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":12,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":12},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001175505","name":"FIVE PRIME THERAPEUTICS INC","url":"/issuer/0001175505","role":"Officer (Chief Strategy Officer)","n_filings":5,"first_seen":"2016-01-29","last_seen":"2017-01-18"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001423786","retrieved_at":"2026-08-22T00:28:43+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}